Judge dismisses Gilead whistleblower suit; Sanofi Canada yanks Allerject lots on needle problems;

@FiercePharma: San Diego's BioAtla gets $30M from mystery Chinese investor in latest round. FiercePharmaAsia story | Follow @FiercePharma

@CarlyHFierce: ICYMI yesterday: What's in a name? For newly transformed Allergan, branded sales. Article | Follow @CarlyHFierce

> Gilead Sciences ($GILD) persuaded a federal judge to toss out a whistleblower lawsuit accusing it of selling its HIV-fighting drugs without getting FDA approval to switch manufacturers. Report

> Sanofi's ($SNY) Canada unit pulled two lots of Allerject auto-injectors because of potentially defective needles. Report

> Pfizer ($PFE) Canada rolled out a copay discount plan designed to persuade patients to keep using its brand-name meds after generics have hit the market. Report

> Planning to expand its philanthropic efforts, AbbVie ($ABBV) created a new position focused on those efforts and tapped a government affairs manager, Melissa Walsh, to fill it. Report

> The FDA's new policies to limit antibiotic use in livestock animals are a step in the right direction, but don't go far enough, some experts say. Report

Medical Device News

@FierceMedDev: ICYMI: Sequenom slapped down in prenatal testing patent battle with Ariosa. Story | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Indian feds stake out plan to become a global hub of device manufacturing and innovation. Story | Follow @VarunSaxena2

@EmilyWFierce: Researchers @TAMHSC are developing a test that could diagnose TB in 10 minutes. More from the WSJ | Follow @EmilyWFierce

> Philips, Siemens score big hospital bundling contracts, highlighting demand for value-based healthcare. Article

> Merck KGaA partner Genea gets CE mark for a pair of IVF technologies. Report

Biotech News

@FierceBiotech: Pulmatrix hits Wall Street with $10M and a Mylan deal. Report | Follow @FierceBiotech

@JohnCFierce: Trending: Why did Briggs Morrison give up R&D leader role at $AZN to run a biotech? Story | Follow @JohnCFierce

@DamianFierce: I just watched Boyz II Men introduce BIO CEO Jim Greenwood and I'm dead now. | Follow @DamianFierce

> Upstart Kezar wrangles $23M to pick up where Onyx left off. Article

> Bayer bets on Johns Hopkins for eye disease R&D. Report

> Avalanche tanks after its gene therapy posts a modest effect on AMD. Story

Pharma Manufacturing News

> Health Canada bans Hospira drugs coming from Italy plant. News

> Pam Cheng leaves Merck for top manufacturing job at AstraZeneca. Item

> India's Polydrug Labs criticized for contaminated APIs. More

> Pfizer supplements its China production with $90M plant. Story

> FDA upgrades standing of Jubilant U.S. sterile plant cited in 2013. Article

Drug Delivery News

> WHO adds postpartum contraceptive ring to 2015 essential meds list. Article

> Study finds Novo's tablet for vaginal atrophy increases compliance compared to creams. Item

> ADA: Nasal powder and artificial pancreas with glucagon both show potential. Story

> Biotie nets $56M+ in IPO, fellow Parkinson's player Cynapsus up next, followed by Intec Pharma. More

> Oculus receives FDA clearance for novel, spray-based wound care formulation. Report

Pharma Asia News

> Japan's PAFSC backs Lilly's dulaglutide, among others, in latest round. News

> NanoCarrier aims for PhI study on neck cancer in Japan for NC-6004. Report

> Video prescriptions, advice, on the cards for hard-pressed patients in Japan. More

> Deputy at China agency that probed GSK arrested for corruption, report says. Story

> China plans to ensure private hospitals get subsidies, finance. Article

And Finally... St. Jude Medical ($STJ) rolled out a pain-relief device controlled by iPod and iPad. Report

Suggested Articles

WuXi AppTec has appointed Celgene CAR-T program veteran David Chang to lead its cell and gene therapy CDMO, WuXi Advanced Therapies.

Maryland-based Emergent BioSolutions has won a $628 million contract with BARDA to manufacture targeted COVID-19 vaccine hopefuls.

About 76% remdesivir patients had at least one point of clinical improvement on a 7-point scale at day 11, versus 66% of patients on standard care.